<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Singh SK</submitter><funding>NIH Office of the Director and MD Anderson Cancer Center Core Grant NIH</funding><funding>NIH Office of the Director</funding><funding>NCI NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>NIH HHS</funding><pagination>e154194</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8983134</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(5)</volume><pubmed_abstract>Understanding the endogenous mechanisms regulating resolution of pain may identify novel targets for treatment of chronic pain. Resolution of chemotherapy-induced peripheral neuropathy (CIPN) after treatment completion depends on CD8+ T cells and on IL-10 produced by other cells. Using Rag2-/- mice lacking T and B cells and adoptive transfer of Il13-/- CD8+ T cells, we showed that CD8+ T cells producing IL-13 were required for resolution of CIPN. Intrathecal administration of anti-IL-13 delayed resolution of CIPN and reduced IL-10 production by dorsal root ganglion macrophages. Depleting local CD206+ macrophages also delayed resolution of CIPN. In vitro, TIM3+CD8+ T cells cultured with cisplatin, apoptotic cells, or phosphatidylserine liposomes produced IL-13, which induced IL-10 in macrop</pubmed_abstract><journal>JCI insight</journal><pubmed_title>CD8+ T cell-derived IL-13 increases macrophage IL-10 to resolve neuropathic pain.</pubmed_title><pmcid>PMC8983134</pmcid><funding_grant_id>R21 NS104804</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>P51 OD011132</funding_grant_id><funding_grant_id>R01 CA227064</funding_grant_id><funding_grant_id>R01 CA208371</funding_grant_id><funding_grant_id>R01 NS116704</funding_grant_id><funding_grant_id>R01 NS073939</funding_grant_id><funding_grant_id>NIH RO1 NS116704 (NINDS),NIH RO1 NS073939 (NINDS),NIH RO1 CA208371 (NCI),NIH RO1 CA227064 (NCI),</funding_grant_id><funding_grant_id>NIH RO1 NS116704 (NINDS),NIH RO1 NS073939 (NINDS),NIH RO1 CA208371 (NCI),NIH RO1 CA227064 (NCI),NIH R21 NS104804 (NINDS),MD Anderson Cancer Center Core Grant NIH P30CA016672</funding_grant_id><funding_grant_id>NIH R21 NS104804 (NINDS)</funding_grant_id><pubmed_authors>Heijnen CJ</pubmed_authors><pubmed_authors>Kavelaars A</pubmed_authors><pubmed_authors>Krukowski K</pubmed_authors><pubmed_authors>Weis D</pubmed_authors><pubmed_authors>Laumet GO</pubmed_authors><pubmed_authors>Alexander JF</pubmed_authors><pubmed_authors>Singh SK</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD8+ T cell-derived IL-13 increases macrophage IL-10 to resolve neuropathic pain.</name><description>Understanding the endogenous mechanisms regulating resolution of pain may identify novel targets for treatment of chronic pain. Resolution of chemotherapy-induced peripheral neuropathy (CIPN) after treatment completion depends on CD8+ T cells and on IL-10 produced by other cells. Using Rag2-/- mice lacking T and B cells and adoptive transfer of Il13-/- CD8+ T cells, we showed that CD8+ T cells producing IL-13 were required for resolution of CIPN. Intrathecal administration of anti-IL-13 delayed resolution of CIPN and reduced IL-10 production by dorsal root ganglion macrophages. Depleting local CD206+ macrophages also delayed resolution of CIPN. In vitro, TIM3+CD8+ T cells cultured with cisplatin, apoptotic cells, or phosphatidylserine liposomes produced IL-13, which induced IL-10 in macrop</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-19T21:48:14.63Z</modification><creation>2025-04-19T21:48:14.63Z</creation></dates><accession>S-EPMC8983134</accession><cross_references><pubmed>35260535</pubmed><doi>10.1172/jci.insight.154194</doi></cross_references></HashMap>